Evaluation of ALN-HTT02 in Adult Patients with Huntington's Disease

The primary objective of this study is to evaluate the efficacy and safety of **ALN-HTT02** in adult patients diagnosed with **Huntington's disease**. This is clinically relevant as Huntington's disease is a progressive neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and psychiatric symptoms, for which there are currently limited treatment options. The study aims to assess the potential of ALN-HTT02 to modify the disease course and improve patient outcomes.

The clinical trial involves a total of **87 participants** diagnosed with **Huntington's disease**. The study population includes both male and female subjects, with an age range spanning from 18 to 64 years. Participants were selected to represent a vulnerable population, although specific selection criteria have not been disclosed by the sponsor. The trial does not specify any particular lifestyle considerations such as diet or physical activity. The general health status of the participants is not detailed, and no additional inclusion or exclusion criteria have been provided. The information available does not include the main objective of the trial.

The clinical trial is designed to evaluate the investigational product ALN-HTT02 in adult patients diagnosed with **Huntington's disease**. This study is structured as a Phase 1 trial, which typically focuses on assessing the safety, tolerability, and pharmacokinetics of the investigational product. The trial is expected to commence recruitment on March 3, 2025, and is projected to conclude by November 30, 2026. The study employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results, minimizing bias and allowing for a robust comparison between the investigational product and a control. Participants will be randomly assigned to either the treatment group receiving ALN-HTT02 or a control group, with neither the participants nor the investigators aware of the group assignments.

The sequence of study visits begins with an inclusion (screening) visit, where potential participants are evaluated against the inclusion and exclusion criteria to determine eligibility. Following successful screening, participants will undergo a series of follow-up visits at predetermined intervals to monitor their health status, assess the effects of the investigational product, and collect necessary data. These visits are crucial for ensuring participant safety and for gathering data on the investigational product's efficacy and safety profile. The trial will culminate in an end-of-study visit, where final assessments are conducted, and participants are debriefed about the study.

The expected length of participant involvement in the trial will vary depending on the specific protocol and individual response to the treatment. However, participants are generally expected to remain in the study for the duration of the trial unless specific conditions necessitate early termination. Such conditions may include adverse reactions to the investigational product, withdrawal of consent, or any other medical or personal reasons deemed significant by the study investigators. The trial is conducted in accordance with ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants throughout the study duration.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of these details limits the ability to describe the treatment regimen comprehensively.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, which typically focuses on assessing safety, tolerability, and pharmacokinetics, but may also include preliminary efficacy assessments. The trial is scheduled to commence recruitment on March 3, 2025, with an estimated completion date of November 30, 2026. Although specific efficacy endpoints and methods for measurement and analysis are not detailed, Phase 1 trials often utilize a combination of laboratory tests, imaging studies, and clinical assessments to gather data on the investigational product's effects. The absence of explicit endpoints suggests that the trial may employ exploratory measures to identify potential efficacy signals. The data collected will be analyzed to determine the investigational product's impact on the targeted condition, contributing to the understanding of its therapeutic potential.